Dual-stage inhibition of Plasmodium falciparum by a Skeletocutis derived fungal metabolite targeting Pyruvate Kinase II

This study identifies skeletocutin E, a fungal metabolite, as a specific dual-stage inhibitor of the apicoplast-localized *Plasmodium falciparum* pyruvate kinase II (PfPyrKII) that effectively blocks parasite growth in both liver and blood stages without affecting human pyruvate kinases, thereby validating PfPyrKII as a promising target for novel antimalarial therapies.

The Gist

The Big Picture: A New Weapon Against a Smart Enemy

Imagine Malaria as a master thief named Plasmodium falciparum. This thief is incredibly good at breaking into houses (human cells) and stealing everything. For years, we've had a "master key" (artemisinin-based drugs) to lock the thief out, but the thief has learned to pick the lock. They are becoming resistant, and our current keys are starting to fail.

Scientists need to find a new type of lock that the thief has never seen before. This paper reports the discovery of a very promising new lock-picking tool (a drug candidate) found in a fungus, which targets a specific, unique part of the thief's machinery that no other drug has successfully attacked yet.

---

The Target: The Parasite's "Power Plant"

Inside the malaria parasite, there is a tiny, specialized factory called the apicoplast. Think of this as the parasite's power plant and supply depot. It doesn't just make energy; it manufactures the raw materials (like bricks and blueprints) the parasite needs to build copies of itself.

To keep this factory running, the parasite uses a specific machine called Pyruvate Kinase II (PfPyrKII).

• The Analogy: Imagine PfPyrKII is the conveyor belt in the factory that turns raw materials into finished products. If you stop the conveyor belt, the factory shuts down, and the parasite dies.
• The Problem: Humans also have conveyor belts (similar enzymes) in our bodies. Most drugs that stop the parasite's belt also stop the human belt, which causes side effects or toxicity. We need a drug that stops only the parasite's belt.

The Discovery: A Fungal "Magic Bullet"

The researchers went on a treasure hunt through a library of chemicals and natural extracts. They found a molecule called Skeletocutin E, which comes from a fungus growing on a tree in Kenya (a Skeletocutis mushroom).

• The Magic: When they tested Skeletocutin E, it acted like a perfectly shaped wrench that jammed only the parasite's conveyor belt (PfPyrKII).
• The Safety: It completely ignored the human conveyor belts. It didn't jam the human machinery at all, meaning it's safe for our cells.

How It Works: The "Mixed" Jam

Usually, drugs work by sitting directly in the "engine" of the machine (the active site) and blocking it. But the researchers found something interesting: Skeletocutin E doesn't block the engine directly.

• The Analogy: Imagine the conveyor belt is a complex robot. Instead of putting gum in the gears, Skeletocutin E sticks to the robot's shoulder. It doesn't stop the gears from turning, but it changes the robot's posture so it can't move its arms effectively.
• The Result: The machine slows down and eventually stops, but the drug isn't fighting for the same spot as the fuel. This is called a "mixed inhibition" mechanism. It's a sneaky way of stopping the machine that the parasite might not be able to easily evolve a defense against.

The Shape-Shifting Machine

The researchers also discovered that the parasite's conveyor belt (PfPyrKII) is weird. Most similar machines in nature are built as solid squares (tetramers). But the parasite's machine is a shapeshifter.

• It exists as a single piece, a pair, a trio, and a square, all at the same time.
• The drug (Skeletocutin E) doesn't try to break the machine apart or glue it together; it just jams the moving parts regardless of the shape. This makes it a very robust target.

Testing the Drug: Stopping the Thief at Two Stages

Malaria has two main phases in humans:

1. The Liver Phase: The parasite hides in your liver, multiplying silently.
2. The Blood Phase: The parasite bursts out of the liver, enters your blood, and causes the fever and sickness.

Most drugs only work on one phase. Skeletocutin E is a dual-threat:

• In the Liver: It stopped the parasite from growing in liver cells (hepatocytes).
• In the Blood: It stopped the parasite from growing in red blood cells.

The Catch: The drug works great in a test tube (where there is no blood serum), but when they added human blood serum (which contains albumin, a protein), the drug seemed to get "distracted" and didn't work as well. It's like the drug got stuck in a net made of blood proteins. However, when they removed the serum for a short time, the drug worked perfectly. This tells scientists they need to tweak the drug slightly so it can slip through the "net" of human blood to reach the parasite.

The Verdict: A Hopeful New Lead

This paper is a major step forward because:

1. New Target: It proves that the parasite's unique "power plant" enzyme is a valid target.
2. New Drug: It found a natural compound that hits this target hard and ignores human cells.
3. Dual Action: It kills the parasite in both the liver and the blood, which is the "holy grail" for malaria treatment (stopping the disease and preventing transmission).

In summary: Scientists found a fungal molecule that acts like a specialized wrench, jamming a unique machine inside the malaria parasite. It stops the parasite in both its hiding spot (liver) and its attack zone (blood), without hurting humans. While it needs a little engineering to work better in human blood, it is a very promising new candidate for a future malaria cure.

Technical Summary

1. Problem Statement

Malaria, caused primarily by Plasmodium falciparum, remains a critical global health burden with rising resistance to artemisinin-based combination therapies (ACTs). There is an urgent need for novel antimalarial drugs with mechanisms of action distinct from current treatments to circumvent cross-resistance.

• Target Gap: While the apicoplast (a plastid-like organelle essential for parasite survival) is a known target, most current drugs targeting it are antibiotics (e.g., doxycycline), which face challenges regarding bacterial resistance and delayed parasite death phenotypes.
• Enzyme Potential: P. falciparum Pyruvate Kinase II (PfPyrKII) is a unique enzyme localized in the apicoplast. Unlike the cytosolic PfPyrKI, PfPyrKII is non-glycolytic and responsible for phosphorylating (d)NDPs to (d)NTPs, which are essential for apicoplast maintenance, DNA replication, and isoprenoid synthesis. Until this study, no specific small-molecule inhibitors for PfPyrKII had been identified.

2. Methodology

The researchers employed a multi-disciplinary approach combining enzymology, structural biology, chemical synthesis, and parasitology:

• Protein Expression & Purification: Recombinant PfPyrKI and PfPyrKII (lacking the apicoplast targeting peptide) were expressed in E. coli and purified.
• Enzymatic Screening & Kinetics: A coupled enzyme assay (using lactate dehydrogenase) monitored NADH oxidation to measure pyruvate kinase activity. A chemical library and natural extracts were screened for inhibitors.
• Mechanism of Action:
  • Kinetic Analysis: Lineweaver-Burk plots were used to determine inhibition types ($K_i$, $K_{ic}$, $K_{iu}$).
  • Mass Photometry: Used to analyze the quaternary structure (monomer, dimer, trimer, tetramer) of PfPyrKII in the presence of inhibitors and substrates.
• Structure-Activity Relationship (SAR): Synthetic analogues of the lead compound were created with varying carbon chain lengths and functional groups to identify molecular determinants of activity.
• Biological Assays:
  • Liver Stage: Primary human hepatocytes (PHH) infected with sporozoites were treated to assess exoerythrocytic form (EEF) development.
  • Blood Stage: P. falciparum growth in human erythrocytes was measured. To overcome serum interference, a serum-free pre-incubation protocol was utilized.
  • Selectivity: Human pyruvate kinases (PKM1, PKM2, PKR) were tested to ensure selectivity.

3. Key Contributions & Results

A. Identification of a Specific Inhibitor

The study identified Skeletocutin E (a Basidiomycete-derived metabolite, 14-carbon chain flanked by two citraconic anhydrides) as a potent and specific inhibitor of PfPyrKII.

• Potency: IC₅₀ of 0.52 ± 0.08 µM against PfPyrKII.
• Selectivity: It showed negligible inhibition of PfPyrKI and three human pyruvate kinase isoforms (PKM1, PKM2, PKR) at 30 µM, confirming high specificity for the parasite target.

B. Mechanism of Inhibition

• Mixed Inhibition: Kinetic analysis revealed a mixed inhibition mechanism. The inhibitor binds to both the free enzyme and the enzyme-substrate complex, with a higher affinity for the enzyme-substrate complex ($K_{iu} < K_{ic}$).
• Binding Site: The inhibitor does not compete directly with the catalytic pocket (which is conserved across species) nor does it disrupt the subunit interfaces.
• Quaternary Structure: Mass photometry revealed a unique quaternary distribution for PfPyrKII, existing as monomers, dimers, trimers, and tetramers in roughly equal proportions (unlike the strict tetrameric nature of most PyrKs). Skeletocutin E did not alter this distribution, suggesting it binds to a specific allosteric site or unstructured loop unique to PfPyrKII.

C. Structure-Activity Relationship (SAR)

• Chain Length Criticality: Synthetic analogues demonstrated that a carbon chain length of at least 14 carbons is essential for inhibitory activity. Shortening the chain drastically reduced potency (IC₅₀ > 10 µM), while lengthening it had less impact.
• Dual Anhydrides: Both citraconic anhydride rings are necessary; single-ring analogues were inactive.

D. Dual-Stage Antimalarial Activity

Skeletocutin E effectively inhibited P. falciparum growth in both life stages:

• Liver Stage: IC₅₀ = 3.70 ± 0.74 µM in primary human hepatocytes. It reduced parasite number and size without toxicity to host cells.
• Blood Stage: IC₅₀ = 3.56 ± 0.50 µM in erythrocytes (under serum-free conditions). In standard serum-containing media, activity was masked by albumin binding, highlighting a need for formulation optimization.
• Toxicity: The compound showed no cytotoxicity to human hepatocytes or red blood cells at effective concentrations.

4. Significance

• Novel Target Validation: This study validates PfPyrKII as a druggable target for malaria, distinct from the cytosolic glycolytic pathway.
• Dual-Stage Efficacy: Skeletocutin E is a rare example of a compound that inhibits both the liver (pre-erythrocytic) and blood stages of the parasite, offering potential for both treatment and transmission blocking.
• Selectivity: The compound's ability to target the apicoplast-localized enzyme while sparing human homologs addresses safety concerns associated with metabolic inhibitors.
• Lead Compound: Skeletocutin E serves as a promising lead for rational drug design. The identified SAR (specifically the 14-carbon chain and dual anhydride structure) provides a blueprint for optimizing bioavailability (e.g., overcoming serum albumin binding) and enhancing potency.

Conclusion

The authors successfully identified Skeletocutin E as a selective, dual-stage inhibitor of P. falciparum targeting the apicoplast enzyme PfPyrKII. By elucidating its mixed inhibition mechanism and unique interaction with the enzyme's quaternary structure, the study establishes a strong foundation for developing a new class of antimalarial drugs capable of overcoming current resistance mechanisms.